Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Z0AM
|
|||
| Former ID |
DNCL001780
|
|||
| Drug Name |
PSI-697
|
|||
| Synonyms |
PSI-697; UNII-LH1XC916ME; 851546-61-7; LH1XC916ME; CHEMBL219046; 2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid; 2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h]quinoline-4-carboxylic acid; SCHEMBL43527; DIEPFYNZGUUVHD-UHFFFAOYSA-N; ZINC28603970; BDBM50201984; AKOS032945074; CS-5867; DB12211; HY-15526; LS-193902; 2-(4-chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]-quinoline-4-carboxylic acid; 2-(4-Chloro-benzyl)-3-hydroxy-7,8,9,10-tetrahydro-benzo[h]quinoline-4-carboxylic
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Atherosclerosis [ICD-11: BD40] | Phase 1 | [1] | |
| Thrombosis [ICD-11: DB61-GB90] | Phase 1 | [1] | ||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H18ClNO3
|
|||
| Canonical SMILES |
C1CCC2=C(C1)C=CC3=C(C(=C(N=C23)CC4=CC=C(C=C4)Cl)O)C(=O)O
|
|||
| InChI |
1S/C21H18ClNO3/c22-14-8-5-12(6-9-14)11-17-20(24)18(21(25)26)16-10-7-13-3-1-2-4-15(13)19(16)23-17/h5-10,24H,1-4,11H2,(H,25,26)
|
|||
| InChIKey |
DIEPFYNZGUUVHD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 851546-61-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P-selectin (SELP) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Malaria | ||||
| Staphylococcus aureus infection | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| amb2 Integrin signaling | ||||
| Reactome | Platelet degranulation | |||
| Cell surface interactions at the vascular wall | ||||
| WikiPathways | Human Complement System | |||
| Spinal Cord Injury | ||||
| Cell surface interactions at the vascular wall | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00367692) Study Evaluating PSI-697 in Patients With Scleritis. U.S. National Institutes of Health. | |||
| REF 2 | Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.